press releases

Date Title  
05/13/21
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 13, 2021-- bluebird bio, Inc . (Nasdaq: BLUE) announced today that data from its gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) and its cell therapy program for relapsed or refractory multiple myeloma (R/RMM)
 
05/05/21
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 5, 2021-- bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational progress. “Undoubtedly the highlight of last quarter at bluebird was the approval of
 
05/03/21
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2021-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: BofA Securities 2021 Health Care Conference , Thursday, May 13 , at 9:30 am ET 2021 RBC Capital
 
04/20/21
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2021-- bluebird bio, Inc. (Nasdaq: BLUE) announced today business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previously reported case of myelodysplastic syndrome (MDS) in its Phase 1/2 study of
 
04/14/21
Single IV cycle of PsiOxus’ T-SIGn vector enabled an otherwise non-effective dose of CAR-T cell therapy to clear primary and metastatic tumors  in vivo Reprogramming of the tumor microenvironment using T-SIGn vectors could enable a variety of CAR-T therapies to overcome limitations in solid tumors
 
03/26/21
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma 1 In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and durable responses 1   Safety profile of Abecma is
 
03/15/21
90% of evaluable patients (27/30) alive and free of major functional disabilities (MFDs) at two years follow-up in Phase 2/3 Starbeam study (ALD-102) Patients in long-term follow-up study (LTF-304) continue to remain alive and MFD-free through up to nearly seven years of follow-up, suggesting
 
03/10/21
Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD bluebird bio has initiated process with regulators to resume clinical studies Company to hold conference call and webcast today, March 10, 2021 , 8:00 AM EST CAMBRIDGE, Mass.
 
02/26/21
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2021-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41 st Annual Health Care Conference , Wednesday, March 3 , at 2:40 p.m. ET . To access the live webcast of bluebird bio’s
 
02/24/21
First pivotal study of BCMA-directed CAR T cell therapy in triple-class exposed relapsed and refractory multiple myeloma Biologics License Application (BLA) for ide-cel was accepted by FDA for Priority Review, with a target action date of March 27, 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.
 
02/23/21
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 23, 2021-- bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress. “For over ten years, bluebird bio has been pioneering
 
02/22/21
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 22, 2021-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 10 th Annual SVB Leerink Global Healthcare Conference , Thursday, February 25 , at 12:00 p.m. ET .
 
02/16/21
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 16, 2021-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that the company has placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) on a temporary suspension due to a reported
 
01/11/21
Severe Genetic Disease business will remain the focus of bluebird bio, Inc.; separation expected to result in two independent, publicly traded companies by year-end 2021 Separation designed to unlock value through improved operational execution, organizational focus, tailored capital allocation,
 

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.